文献速递认知障碍与痴呆

预防轻度认知障碍黑人个体的认知衰退:一项随机临床试验

Preventing Cognitive Decline in Black Individuals With Mild Cognitive Impairment: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2018-01-01

这项单中心、单盲、注意力对照随机临床试验纳入221例65岁以上遗忘型轻度认知障碍黑人个体,随机分入行为激活组或支持性治疗组,随访2年。行为激活组记忆衰退2年发生率为1.2%,支持性治疗组为9.3%(相对风险0.12,P=0.02),行为激活与稳定的日常功能相关。作者结论认为行为激活预防了认知和功能衰退,但该发现需进一步研究。

要点

  • 行为激活组2年记忆衰退发生率为1.2%,支持性治疗组为9.3%(相对风险0.12,95%CI 0.02-0.74,P=0.02)。
  • 行为激活与稳定的日常功能相关,支持性治疗与功能下降相关(斜率差异2.71,95%CI 0.12-5.30,P=0.04)。
  • 作者结论认为行为激活预防了认知和功能衰退,但该发现需进一步研究。

核心结论

  • 行为激活预防了认知和功能衰退,但该发现需进一步研究。
  • 黑人个体的痴呆发生率几乎是白人的两倍;行为激活可能减少这一健康差异。

研究设计与样本

  • 单中心、单盲、注意力对照随机临床试验,参与者于2011年6月21日至2014年10月3日入组,随访于2016年12月13日结束。
  • 社区招募并治疗65岁以上遗忘型轻度认知障碍黑人个体,筛查1390例有记忆主诉者,536例完成基线评估,315例(58.8%)不符合条件,最常见原因为认知正常(205/315,65%)或痴呆(59/315,18.7%),最终221例完全符合条件的参与者被随机分组。
  • 参与者随机分入行为激活组(111例,50.2%)或支持性治疗组(110例,49.8%),行为激活旨在增加认知、体力和社会活动,支持性治疗为注意力对照治疗;分析为意向性治疗分析。

主要发现

  • 221例随机参与者平均(标准差)年龄75.8(7.0)岁,女性175例(79%);行为激活组77例(69.4%)和支持性治疗组87例(79.1%)完成了2年结局评估。
  • 基线后,行为激活组参与者参与的认知活动显著多于支持性治疗组。
  • 2年记忆衰退发生率行为激活组为1.2%(95%CI 0.2-6.4),支持性治疗组为9.3%(95%CI 5.30-16.4),相对风险0.12(95%CI 0.02-0.74;P=0.02)。
  • 行为激活与稳定的日常功能相关,而支持性治疗与功能下降相关(斜率差异2.71;95%CI 0.12-5.30;P=0.04)。
  • 严重不良事件发生率行为激活组与支持性治疗组分别为:跌倒(14例[13%] vs 28例[25%])、急诊就诊(24例[22%] vs 24例[22%])、住院(36例[32%] vs 31例[28%])、死亡(7例[5%] vs 3例[4%])。

关键数值与推荐

  • 预设主要结局为霍普金斯词语学习测验修订版总回忆评分在6、12、18和24个月时回忆单词数下降6个或以上。
  • 次要结局为功能衰退。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者结论指出该发现需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Mild cognitive impairment (MCI) is a transition state between normal cognitive aging and dementia that increases the risk for progressive cognitive decline. Preventing cognitive decline is a public health priority. OBJECTIVE: To determine whether behavioral activation prevents cognitive and functional decline over 2 years in black individuals with MCI. DESIGN, SETTING, AND PARTICIPANTS: Single-center, single-masked, attention-controlled randomized clinical trial. Participants were enrolled from June 21, 2011, to October 3, 2014, and follow-up ended December 13, 2016. Community-based recruitment and treatment of black individuals older than 65 years with amnestic MCI. Volunteer sample of 1390 persons with memory complaints were screened. Overall, 536 individuals had baseline assessment, and 315 (58.8%) were ineligible, most often owing to normal cognition (205 of 315 [65%]) or dementia (59 of 315 [18.7%]); 221 fully eligible participants were randomized. Analyses were intention to treat. INTERVENTIONS: Participants were randomized to behavioral activation, which aimed to increase cognitive, physical, and social activity (111 [50.2%]), or supportive therapy, an attention control treatment (110 [49.8%]). MAIN OUTCOMES AND MEASURES: The prespecified primary outcome was a decline of 6 or more recalled words on the total recall score of the Hopkins Verbal Learning Test-Revised assessed at 6, 12, 18, and 24 months. The secondary outcome was functional decline. RESULTS: Of 221 randomized participants (mean [SD] age, 75.8 [7.0] years, 175 women [79%]), 77 behavioral activation participants (69.4%) and 87 supportive therapy participants (79.1%) had 2-year outcome assessments. After baseline, behavioral activation participants engaged in significantly more cognitive activities than supportive therapy participants. The 2-year incidence of memory decline was 1.2% (95% CI, 0.2-6.4) for behavioral activation vs 9.3% (95% CI, 5.30-16.4) for supportive therapy (relative risk, 0.12; 95% CI, 0.02-0.74; P = .02). Behavioral activation was associated with stable everyday function, whereas supportive therapy was associated with decline (difference in slopes, 2.71; 95% CI, 0.12-5.30; P = .04). Rates of serious adverse events for behavioral activation and supportive therapy, respectively, were: falls (14 [13%] vs 28 [25%]), emergency department visits (24 [22%] vs 24 [22%]), hospitalizations (36 [32%] vs 31 [28%]), and deaths (7 [5%] vs 3 [4%]). CONCLUSIONS AND RELEVANCE: Behavioral activation prevented cognitive and functional decline, but this finding requires further investigation. Black individuals have almost twice the rate of dementia as white individuals; behavioral activation may reduce this health disparity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01299766.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Rovner BW, Casten RJ, Hegel MT, et al. Preventing Cognitive Decline in Black Individuals With Mild Cognitive Impairment: A Randomized Clinical Trial. JAMA Neurol. 2018. PMID: 30208380. doi:10.1001/jamaneurol.2018.2513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。